Also, our findings underscore the potential of new anticancer variants of LKB1, opening new avenues for innovative treatments using CRISPR technology to benefit cancer patients or individuals with diseases associated with LKB1 mutations like PJS. This evidence concerns the gene STK11 and cancer.